Search

Alvernia F Setiadi

from San Carlos, CA
Age ~47

Alvernia Setiadi Phones & Addresses

  • 1040 San Remo Way, San Carlos, CA 94070
  • Sunnyvale, CA

Publications

Us Patents

Hat Acetylation Promoters And Uses Of Compositions Thereof In Promoting Immunogenicity

View page
US Patent:
20100166781, Jul 1, 2010
Filed:
Jul 17, 2009
Appl. No.:
12/504775
Inventors:
Alvernia F. Setiadi - Sunnyvale CA, US
Muriel David - Le Plessis Robinson, FR
Robyn P. Seipp - Vancouver, CA
Jennifer Hartikainen - Vancouver, CA
Rayshad Gopaul - Vancouver, CA
Wilfred Arthur Jefferies - Surrey, CA
Assignee:
Tapimmune, Inc. - Vancouver
International Classification:
A61K 39/00
A61K 31/165
A61K 38/45
A61K 31/473
A61K 38/07
A61P 35/00
A61P 31/12
C12Q 1/34
US Classification:
4241841, 514575, 424 945, 514296, 514 11, 435 18
Abstract:
The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.

Diagnostic And Therapeutic Methods For Irak4-Mediated Disorders And Conditions

View page
US Patent:
20200103418, Apr 2, 2020
Filed:
Dec 13, 2019
Appl. No.:
16/713638
Inventors:
- South San Francisco CA, US
Alvernia Francesca SETIADI - San Carlos CA, US
Michael TOWNSEND - San Jose CA, US
Ali A. ZARRIN - Brisbane CA, US
International Classification:
G01N 33/68
A61K 31/473
A61K 31/675
Abstract:
The present invention provides diagnostic and therapeutic methods and compositions for treating a patient suffering from an interleukin-1 receptor-associated kinase 4 (IRAK4)-mediated disorder or condition, such as an immune disorder (e.g., systemic lupus erythematosus (SLE)) or an inflammatory disorder (e.g., asthma). The invention provides diagnostic methods of monitoring the response of a patient having an IRAK4-mediated disorder or condition to treatment including an IRAK4 pathway inhibitor, methods of identifying a patient having an IRAK4-mediated disorder or condition who may benefit from treatment including an IRAK4 pathway inhibitor, and methods of selecting a therapy for a patient having an IRAK4-mediated disorder or condition based on the expression level of one or more IRAK4 biomarkers (e.g., one or more genes set forth in Table 1). Related therapeutic methods and compositions (e.g., diagnostic kits) are also provided.

Gene Expression Markers And Treatment Of Multiple Sclerosis

View page
US Patent:
20180080080, Mar 22, 2018
Filed:
Jul 27, 2017
Appl. No.:
15/662079
Inventors:
- South San Francisco CA, US
ALVERNIA FRANCESCA SETIADI - SAN CARLOS CA, US
TRACY STATON - STANFORD CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
C12Q 1/68
C07K 16/24
G01N 33/564
Abstract:
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Alvernia F Setiadi from San Carlos, CA, age ~47 Get Report